"10.1371_journal.pmed.1000292","plos medicine","2010-06-15T00:00:00Z","Marc A Rodger; Marisol T Betancourt; Peter Clark; Pelle G Lindqvist; Donna Dizon-Townson; Joanne Said; Uri Seligsohn; Marc Carrier; Ophira Salomon; Ian A Greer","Thrombosis Program, Division of Hematology, Departments of Medicine, Obstetrics and Gynecology and Epidemiology/Community Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada; Department of Transfusion Medicine, Ninewells, Hospital and Medical School, Dundee, United Kingdom; Department of Obstetrics and Gynecology, Karolinska Hospital, Huddinge, Sweden; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, Bethesda, Maryland; Department of Perinatal Medicine, The Royal Womens Hospital, Carlton, Victoria Australia; Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria, Australia; The Amalia Biron Thrombosis and Hemostasis Research Institute, the Chaim Sheba Medical Center, Tel Hashomer, Israel; Hull York Medical School, York, United Kingdom","ICMJE criteria for authorship read and met: MAR MTB PC PGL DDT JS US MC OS IAG. Agree with the manuscripts results and conclusions: MAR MTB PC PGL DDT JS US MC OS IAG. Designed the experiments/the study: MAR MTB DDT IAG. Analyzed the data: MAR MTB DDT. Collected data/did experiments for the study: MAR MTB PC PGL DDT JS US OS IAG. Enrolled patients: MAR DDT JS US OS IAG. Wrote the first draft of the paper: MAR MTB MC. Contributed to the writing of the paper: MAR MTB PC PGL DDT JS MC IAG. Wrote the final version of the study protocol: MAR. Designed search strategy, conducted literature searches, and extracted data: MTB. Critical revising and final approval of the paper: PGL.","MAR is the principal investigator of a Canadian Institutes of Health Research randomised trial comparing dalteparin to no dalteparin to prevent placenta-mediated pregnancy complications in thrombophilic women. MAR has received grant funding from Pfizer, Sanofi, Boehringer Ingelheim, Bayer, GTC Therapeutics, and Leo Pharma. MAR has also served on advisory boards for Boehringer Ingelheim and Biomerieux but not been paid. IAG has received Honoraria for lectures and advisory boards from Sanofi Aventis and Leo Pharma.","2010","06","Marc A Rodger","MAR",10,TRUE,NA,NA,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
